Filtered By:
Condition: Huntington's Disease
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 289 results found since Jan 2013.
Neuroprotective Potential of Caffeic Acid Phenethyl Ester (CAPE) in CNS Disorders: Mechanistic and Therapeutic Insights
Curr Neuropharmacol. 2021 Jun 8. doi: 10.2174/1570159X19666210608165509. Online ahead of print.ABSTRACTNeurological disorders like Alzheimer's disease (AD), Parkinson's disease (PD), stroke, amyotrophic lateral sclerosis, Huntington's disease (HD), epilepsy, traumatic brain injury (TBI), depression and anxiety are responsible for thousands of deaths worldwide every year. With the increase in life expectancy, there has been a rise in the prevalence of these disorders. Age is one of the major risk factors for these neurological disorders and with the aged population is set to rise to 1.25 billion by 2050. There is a growing ...
Source: Current Neuropharmacology - June 9, 2021 Category: Drugs & Pharmacology Authors: Namrata Pramod Kulkarni Bhupesh Vaidya Acharan Narula Shyam Sunder Sharma Source Type: research
Highlighting the protective or degenerative role of AMPK activators in dementia experimental models
CNS Neurol Disord Drug Targets. 2021 May 26. doi: 10.2174/1871527320666210526160214. Online ahead of print.ABSTRACTAMP-activated protein kinase (AMPK) is a serine/threonine kinase and a driving or deterrent factor in the development of neurodegenerative diseases and dementia. AMPK affects intracellular proteins like the mammalian target of rapamycin (mTOR). Peroxisome proliferator-activated receptor-γ coactivator 1-α (among others) contributes to a wide range of intracellular activities based on its downstream molecules such as energy balancing (ATP synthesis), extracellular inflammation, cell growth, and neuronal cell d...
Source: CNS and Neurological Disorders Drug Targets - May 27, 2021 Category: Drugs & Pharmacology Authors: Marjan Nikbakhtzadeh Fatemeh Shaerzadeh Ghorbangol Ashabi Source Type: research
Repurposing Vorinostat for the Treatment of Disorders Affecting Brain
AbstractBased on the findings in recent years, we summarize the therapeutic potential of vorinostat (VOR), the first approved histone deacetylase (HDAC) inhibitor, in disorders of brain, and strategies to improve drug efficacy and reduce side effects. Scientific evidences provide a strong case for the therapeutic utility of VOR in various disorders affecting brain, including stroke, Alzheimer ’s disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, X‐linked adrenoleukodystrophy, epilepsy, Niemann-Pick type C disease, and neuropsychiatric dis...
Source: NeuroMolecular Medicine - May 4, 2021 Category: Neurology Source Type: research
